secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-045761
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023
--------------------------------------------------------------------------------

- Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).
- Gross margin improved to 45.6% from 44.3%; adjusted EBITDA loss narrowed to $0.8M from $2.3M.
- Cash balance $0.5M at year-end vs $1.3M; net proceeds of $0.9M from Streeterville financing in Q3 2024.
- Acquired Elevated Softgels in Q2 2024; launched +PlusHLTH brand and Lunar Fox plant-based line.
- Retained Maxim Group as non-exclusive financial advisor; evaluating M&A opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000095017025045761/0000950170-25-045761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000095017025045761/cvsi-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer